CSPCY (CSPC Pharmaceutical Group) PEG Ratio: N/A (As of Jul. 01, 2026)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
79 GF Score
Price $3.55
GF Value $3.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, CSPC Pharmaceutical Group's PE Ratio without NRI is 23.83. CSPC Pharmaceutical Group's 5-Year EBITDA growth rate is -4.30%. Therefore, CSPC Pharmaceutical Group's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for CSPC Pharmaceutical Group's PEG Ratio or its related term are showing as below:


During the past 13 years, CSPC Pharmaceutical Group's highest PEG Ratio was 15.03. The lowest was 0.55. And the median was 1.37.


CSPCY's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


CSPC Pharmaceutical Group  (OTCPK:CSPCY) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


CSPC Pharmaceutical Group PEG Ratio Related Terms


CSPC Pharmaceutical Group PEG Ratio Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group PEG Ratio Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.90 0.03 0.04 0.00

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.38 0.00 0.00 0.00 0.00

CSPCY vs LLY, JNJ, ABBV: PEG Ratio Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's PEG Ratio distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's PEG Ratio falls into.


CSPCY
79GF Score
CSPC Pharmaceutical Group Ltd CSPCY
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

CSPC Pharmaceutical Group's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=23.825503355705/-4.30
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $3.55 is trading 7.3% above its estimated GF Value™ of $3.31. GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.

Key valuation signals for CSPCY:

  • PEG Ratio: N/A
  • GF Value™: $3.31 vs. price of $3.55 (7.3% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
79GF Score

Get the complete analysis for CSPCY

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price
$3.31
GF Value